Krause und Pachernegg
Verlag für Medizin und Wirtschaft
Artikel   Bilder   Volltext

Mobile Version
A-  |   A  |   A+
Werbung
 
Dia-Präsentation von Merck Gesellschaft mbH.
Micardis(R) - Micardis Plus(R) - Laufende Studien (6 Abbildungen)
Übersicht


Zum ersten Bild Abb. 0: FÜR ÖSTERREICH: Weitere Informationen: Merck Gesellschaft mbH, Zimbagasse 5, 1147 Wien, Tel.: 01/576 00-0 Abb. 1: Laufende Studien Abb. 2: PROTECTION Abb. 3: ProFESS Aktuelles Bild - Abb. 4: Ontarget/Transcend Abb. 5: PROTECTION - Ontarget Abb. 6: Zusammenfassung
Abbildung 4: Ontarget/Transcend
The ONgoing Telmisartan Alone and in combination with Ramipril Global Endpoint Trial (ONTARGET) Programme is one of the largest cardiovascular protection trials ever undertaken.1,2 ONTARGET will compare telmisartan, ramipril and the combination over a study period of 5.5 years. The parallel Telmisartan Randomized AssessmeNt Study in ACE inhibitor-iNtolerant subjects with cardiovascular Disease (TRANSCEND) will compare telmisartan with placebo in patients intolerant of ACE inhibitors, and has the same endpoints. Patients enrolled are aged 55 years and are at high risk of cardiovascular events (i.e., they have a history of coronary artery disease, peripheral vascular disease, stroke or recent ischaemic attack, or diabetes mellitus type 1 or 2 with target-organ damage). ONTARGET will incorporate a number of endpoints, including cardiovascular mortality and morbidity, new cases of diabetes, nephropathy and cognitive decline. Zimmerman M, Unger T. Challenges in improving prognosis and therapy: the Ongoing Telmisartan Alone and in Combination with Ramipril Global End point Trial Programme. Exp Opin Pharmacother 2004;5:1201–1208. The ONTARGET/TRANSCEND Investigators. Rationale, design and baseline characteristics of two, large, simple, randomized trials evaluating telmisartan, ramipril and their combination in high-risk patients: the ONTARGET/TRANSCEND trials. Am Heart J 2004; 148: 52–61.
 
Ontarget/Transcend
Vorheriges Bild Nächstes Bild   


Abbildung 4: Ontarget/Transcend
The ONgoing Telmisartan Alone and in combination with Ramipril Global Endpoint Trial (ONTARGET) Programme is one of the largest cardiovascular protection trials ever undertaken.1,2 ONTARGET will compare telmisartan, ramipril and the combination over a study period of 5.5 years. The parallel Telmisartan Randomized AssessmeNt Study in ACE inhibitor-iNtolerant subjects with cardiovascular Disease (TRANSCEND) will compare telmisartan with placebo in patients intolerant of ACE inhibitors, and has the same endpoints. Patients enrolled are aged 55 years and are at high risk of cardiovascular events (i.e., they have a history of coronary artery disease, peripheral vascular disease, stroke or recent ischaemic attack, or diabetes mellitus type 1 or 2 with target-organ damage). ONTARGET will incorporate a number of endpoints, including cardiovascular mortality and morbidity, new cases of diabetes, nephropathy and cognitive decline. Zimmerman M, Unger T. Challenges in improving prognosis and therapy: the Ongoing Telmisartan Alone and in Combination with Ramipril Global End point Trial Programme. Exp Opin Pharmacother 2004;5:1201–1208. The ONTARGET/TRANSCEND Investigators. Rationale, design and baseline characteristics of two, large, simple, randomized trials evaluating telmisartan, ramipril and their combination in high-risk patients: the ONTARGET/TRANSCEND trials. Am Heart J 2004; 148: 52–61.
 
copyright © 2003–2017 Krause & Pachernegg GmbH | Sitemap | Impressum
 
Werbung